GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allied Corp (OTCPK:ALID) » Definitions » Debt-to-EBITDA

Allied (Allied) Debt-to-EBITDA : -2.49 (As of Feb. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Allied Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Allied's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $6.15 Mil. Allied's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $0.10 Mil. Allied's annualized EBITDA for the quarter that ended in Feb. 2024 was $-2.51 Mil. Allied's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2024 was -2.49.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Allied's Debt-to-EBITDA or its related term are showing as below:

ALID' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.78   Med: -0.37   Max: -0.33
Current: -0.78

During the past 6 years, the highest Debt-to-EBITDA Ratio of Allied was -0.33. The lowest was -0.78. And the median was -0.37.

ALID's Debt-to-EBITDA is ranked worse than
100% of 659 companies
in the Drug Manufacturers industry
Industry Median: 1.71 vs ALID: -0.78

Allied Debt-to-EBITDA Historical Data

The historical data trend for Allied's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allied Debt-to-EBITDA Chart

Allied Annual Data
Trend Mar18 Mar19 Aug20 Aug21 Aug22 Aug23
Debt-to-EBITDA
Get a 7-Day Free Trial - -0.33 -0.39 -0.36 -0.61

Allied Quarterly Data
Mar19 Jun19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.78 -0.76 -0.30 -2.53 -2.49

Competitive Comparison of Allied's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Allied's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allied's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allied's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Allied's Debt-to-EBITDA falls into.



Allied Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Allied's Debt-to-EBITDA for the fiscal year that ended in Aug. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.763 + 0.099) / -9.675
=-0.61

Allied's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.15 + 0.096) / -2.508
=-2.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Feb. 2024) EBITDA data.


Allied  (OTCPK:ALID) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Allied Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Allied's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Allied (Allied) Business Description

Traded in Other Exchanges
N/A
Address
1405 St. Paul Street, Suite 201, Kelowna, BC, CAN, V1Y 9N2
Allied Corp is an international cannabis company with a mission to help people suffering from Post-Traumatic Stress Disorder (PTSD) by researching, creating, and producing targeted cannabinoid health solutions. The company uses an evidence-informed scientific approach to make this mission possible through cutting-edge pharmaceutical research and development, plant-based production, and the development of therapeutic products. The company operates in two segments which include Allied and Allied Colombia. Its geographical segments consist of Colombia and Canada. The company's revenue is comprised ofsales ofcannabis products.
Executives
James George Robinson director, 10 percent owner 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Anthony Zelen director, 10 percent owner 1406 MINE HILL LANE, KELOWNA A1 V1P 1S5
Calum Hughes director, 10 percent owner, officer: Chief Executive Officer 1847 CROSSGLEN COURT, KELOWNA A1 V1V 1S4
David Weinkauf director, 10 percent owner, officer: Chief Business Development Off 192 SIERRA MORENA LANDING, SW CALGARY A0 T3H 4K4
Paul James Bullock director, 10 percent owner, officer: Chief Operating Officer 1400 ST PAUL ST, SUITE 201, KELOWNA Z4 V1Y9N2